Anxiety is an emotional response that occurs as a result of stimuli that break the physiological and psychological balance by acting as a defense system for the body. Psychological and pharmacological therapies may be effective in the short term for symptom relief, but the data show that long-term pharmacological treatment (several years) is ineffective in a considerable percentage of patients. The lack of effect of the pharmacological treatment of anxiety and insomnia may be due in large part to genetic causes, since the variation in the human genome is one of the most important factors responsible for modulating the individual response to medications.
The genetic profile FG – Neuro Anxiety studies the main metabolizing enzymes, carriers and targets involved in the metabolism of anxiolytic and hypnotic drugs. The analysis provides relevant information on the 13 most commonly used drugs, from the study of 22 genetic polymorphisms described in the six main enzymes of the cytochrome P450 system: CYP2D6, CYP2C9, CYP2C19, CYP3A4, CYP3A5 and CYP1A2.
• Patients on pharmacological treatment who wish to customize medication based on their genetic profile
• Patients with drug side effects
• Patients in whom pharmacological treatments do not show the expected results
Next Generation Sequencing (NGS)
• Guaranteed from the experience of the Synlab group, the absolute European leader in laboratory diagnosis.
• Detailed report including, in addition to the type of metabolism of each enzyme, which drugs can generate toxic effects and adverse reactions, as well as dose recommendations.
• Information provided by the analysis allows the selection of the most appropriate drug, and determines the most appropriate dose for each patient.
• Genetic counseling available at no additional cost, according to the needs of each client.
DOCUMENTATION – Available on Extranet for clients:
• Informed Consent
• Clinical Questionnaire
• Fasting is not necessary for the test.